Zytoservice
Zytoservice is a German pharmaceutical manufacturer producing patient-specific cytostatic and sterile parenteral infusions for pharmacies, hospitals, and clinics across Germany. Operating two GMP-certified cleanroom production sites with 400+ employees and 500,000+ units produced annually.
- Company typePrivate
- Founded2002
- HeadquartersHamburg, Germany
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zytoservice does
ZytoService Deutschland GmbH is a Hamburg-headquartered German pharmaceutical manufacturer founded in 2002 that specializes in producing patient-specific parenteral infusion solutions, primarily cytostatic (chemotherapy) infusions, manufactured to the individual specifications of attending physicians for cancer patients treated in clinics and hospitals. The company operates two production sites in Hamburg and Leipzig and reports more than 400 employees producing over half a million cytostatic drugs, parenteral nutrition products, antibiotics, and other sterile infusion solutions each year. Production takes place in the highest cleanroom class under European Commission GMP (Good Manufacturing Practice) requirements, and ZytoService is also licensed to manufacture clinical trial products, having completed more than 150 studies in oncology and immunology.
The core technology is GMP-certified sterile compounding in highest-class cleanrooms, with each patient order produced to a unique specification on behalf of pharmacies. The service portfolio includes Pharmaceutical Production, Clinical Studies Services, Oncological Care Services (personal consulting for pharmacies and outpatient departments), an internal Academy for specialist training, and integrated GMP Quality Control and Quality Assurance modules. ZytoService claims to be the only company in Germany producing patient-specific cytostatic infusions under these highest GMP standards.
The business model is B2B pharmaceutical manufacturing services, with revenue derived from per-patient custom manufacturing orders placed by pharmacies and hospitals. Pricing is not publicly disclosed because each order is bespoke. The company is a member of the alanta health group, operates exclusively in Germany, and is led by Managing Directors Dr. Mirco Schäcke (Business Administration) and Pia Sundermann (Pharmacist, MBA Health Management). The company is privately held as a GmbH with no public funding or revenue disclosure.
Zytoservice firmographics
Firmographics- Name
- Zytoservice
- Legal name
- ZytoService Deutschland Gesellschaft mit beschränkter Haftung
- Website
- https://zytoservice.de
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Short description
- Zytoservice is a German pharmaceutical manufacturer producing patient-specific cytostatic and sterile parenteral infusions for pharmacies, hospitals, and clinics across Germany. Operating two GMP-certified cleanroom production sites with 400+ employees and 500,000+ units produced annually.
- Ownership category
- akta.pro rank
Zytoservice industry classification
Industry- Product category
- Pharmaceutical Manufacturing Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
- akta.pro secondary industries
- Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE), Infusion Therapy Centers (Outpatient) (HLAFABAF)
Keywords
Where Zytoservice is headquartered
LocationHeadquarters
- HQ city
- Hamburg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Zytoservice business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- Pharmaceutical manufacturing services: Manufacturing cytostatic infusions, parenteral nutrition products, antibiotics, and other sterile infusion solutions for pharmacies and hospitals on a per-patient basis.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Zytoservice product offering
Product offeringCore offering
ZytoService manufactures patient-specific parenteral infusion solutions — primarily cytostatic (chemotherapy) infusions — on behalf of pharmacies according to individual physician specifications. Production takes place in highest-class cleanroom sterile laboratories under European Commission GMP guidelines, with additional offerings in clinical trial manufacturing, oncological care support, and internal academy training.
Product overview
ZytoService is a pharmaceutical manufacturing company offering a portfolio of patient-specific parenteral infusion solutions and related services. The core offering is Pharmaceutical Production of cytostatic infusions manufactured uniquely for each patient. This is complemented by Clinical Studies Services (conducting over 150 clinical trials in oncology and immunology), Oncological Care Services providing personal support to pharmacies and outpatient departments, and Academy services for employee training. Quality is ensured through integrated GMP Quality Control and Quality Assurance modules. All products are manufactured in the highest cleanroom class following European Commission GMP requirements.
Differentiator
Problem solved
Functional benefit
Products and services
- Patient-Specific Parenteral Infusion Solutions Manufactures patient-specific cytostatic infusions, parenteral nutrition products, antibiotics, and other sterile parenteral solutions uniquely prepared for each individual patient, produced under European Commission GMP guidelines. Delivered on behalf of pharmacies to hospitals and clinics for cancer patient treatment.
- Clinical Studies Services As a licensed pharmaceutical manufacturer for clinical trial products, ZytoService produces investigational parenteral formulations and conducts clinical studies in oncology and immunology on behalf of trial sponsors.
- Oncological Care Services Service offering for pharmacies and hospital outpatient departments providing personal customer care, professional pharmaceutical consulting, flexibility, and complete reliability in the supply of patient-specific oncological therapies.
Quantifiable outcome
- Over 500,000 cytostatic drugs and sterile infusion solutions produced annually
- +1 more outcomes
Companies that use Zytoservice
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
Zytoservice technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Zytoservice partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- alanta health groupparent companyZytoService is a member of the alanta health group, operating as a pharmaceutical manufacturing company within the group structure.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Zytoservice competitors and assessment
Company assessmentDirect peers
- Alcami: US-based CDMO with sterile injectable development and manufacturing capabilities including small-batch oncology and specialty infusion production for hospitals and pharma companies.
- EVER Pharma: Austria/Germany-based specialty pharmaceutical company with a portfolio of sterile injectable neurology and oncology products, comparable in scale, geography, and sterile manufacturing focus.
- Curia (formerly AMRI): Global CDMO providing sterile fill-finish and injectable manufacturing services, comparable as a contract manufacturer serving pharmaceutical and healthcare customers with sterile products.
- B. Braun: Global German-headquartered medical and pharmaceutical company with a large sterile solutions, infusion, and parenteral nutrition manufacturing business that overlaps directly with ZytoService's infusion production activities.
- Hameln Pharma: German-based specialty sterile injectable manufacturer focused on aseptic production of small-batch parenteral products, highly comparable to ZytoService's patient-specific infusion manufacturing model.
- Fresenius Kabi: Major German-headquartered manufacturer of injectable pharmaceuticals, infusion solutions, and clinical nutrition products with deep overlap in sterile injectable and infusion therapy manufacturing.
- Central Admixture Pharmacy Services (CAPS): Largest network of FDA-inspected 503B outsourcing facilities in the US, producing sterile admixture preparations including oncology infusions — directly comparable outsourced compounding model to ZytoService.
Broad incumbents
- Pfizer CentreOne: Contract manufacturing arm of Pfizer offering sterile injectable and API manufacturing; comparable service line but operates as part of a much larger global pharmaceutical portfolio.
- Baxter International: Large diversified manufacturer of sterile injectable and IV solutions globally, overlapping with ZytoService's infusion and sterile manufacturing business as part of a broader hospital products portfolio.
- Sanofi: Global pharmaceutical company with significant oncology and injectable product manufacturing footprint that overlaps with ZytoService's therapeutic focus, though at vastly larger scale and broader scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Zytoservice social profiles
Digital presenceZytoservice financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zytoservice leadership team
Management profileNumber of profiles
Profiles2 records
Zytoservice funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zytoservice M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zytoservice
What does Zytoservice do?
ZytoService manufactures patient-specific parenteral infusion solutions — primarily cytostatic (chemotherapy) infusions — on behalf of pharmacies according to individual physician specifications. Production takes place in highest-class cleanroom sterile laboratories under European Commission GMP guidelines, with additional offerings in clinical trial manufacturing, oncological care support, and internal academy training.
Is Zytoservice a public or private company?
Zytoservice is a private company. It is classified as corporate owned and is currently operating.
When was Zytoservice founded?
Zytoservice was founded in 2002.
Where is Zytoservice based?
Zytoservice is headquartered in Hamburg, Germany, in the Europe region.
How does Zytoservice make money?
One revenue line is on record: pharmaceutical manufacturing services.
Who are Zytoservice's main competitors?
Direct peers on record are Alcami, EVER Pharma, Curia (formerly AMRI), B. Braun, Hameln Pharma, Fresenius Kabi and Central Admixture Pharmacy Services (CAPS). Broad incumbents are Pfizer CentreOne, Baxter International and Sanofi.
Does Zytoservice have an API?
No public API is recorded for Zytoservice.
What industry is Zytoservice in?
Zytoservice's product category is Pharmaceutical Manufacturing Services. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile). Its NAICS code is 325412 and its SIC code is 2834.